ClinicalTrials.gg
CompletedNCT03467932Updated Nov 8, 2022Results posted

A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus

A Phase 2 interventional study of Cohort A: ORMD-0801 and Placebo oral capsule in T2DM (Type 2 Diabetes Mellitus), sponsored by Oramed, Ltd.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-08.

Sponsored by Oramed, Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
373
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States — 343 open to participants now, 478 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.

Enrollment
621st of 2,957
373 · median 90
Started
2018
with 125 others
Phase 2
391 of 3,304
24 open now
Registered
2,063rd of 3,304
by date

Among the 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 621st largest by enrollment of the 2,957 interventional ones that give a count, is one of 126 that started in 2018, is one of 391 in phase 2, and was the 2,063rd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

343 of the 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:

338 more — sign in →

All 343 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States, or all of them as a file.
02

Study summary

This is a four-way (Participant, Care Provider, Investigator, Outcomes Assessor) masked (blinded) study designed to explore the efficacy of ORMD-0801 when given in different regimens across a dose range for up to 12 weeks in subjects with type 2 diabetes mellitus (T2DM).

Read the detailed description

This study is designed to explore the efficacy of ORMD-0801 when given in different regimens across a dose range for up to 12 weeks in subjects with type 2 diabetes mellitus (T2DM). There are two cohorts in this study. Approximately 360 subjects with T2DM will initially undergo a 2-week, single-blind placebo run-in period (Visits 1 and 2), followed by a 12-week treatment period (Visits 3 through 9). Cohort A will enroll 285 subjects; Cohort B will enroll 75 subjects

For 265 of the 285 subjects of Cohort A, the total 12-week treatment period will include a Part 1"dose escalation" interval (2 weeks, Visits 3 and 4) and a Part 2 stable dose "maintenance" interval (10 weeks, Visits 5 through 9).

In addition, per FDA request, the remaining 20 subjects (of the cohort total of 285 enrolled subjects) will receive excipient-matched placebo in a non-randomized single-blind fashion, TID (3 times per day), according to the same schedule as described above.

For Cohort B (75 of the 360 total subjects), the total 12-week treatment period will include a stable dosing period for both Part 1 (2 weeks, Visits 3 and 4) and Part 2 (10 weeks, Visits 5 through 9).

Cohort A data will be analyzed after Cohort A data collection has been completed (last subject for Cohort A screened on 7 May 2019). Estimated completion for Cohort A is October 2019. Cohort B data will be analyzed following the release of results from Cohort A.

03

Conditions studied

  • T2DM (Type 2 Diabetes Mellitus)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects aged 18 and older.
  • Established diagnosis of T2DM for at least 6 months prior to Screening, with an (glycated hemoglobin) ≥ 7.5%.
  • Stable dose of metformin (at least 1500 mg or maximally tolerated dose)/oral antidiabetic (OAD) for a period of at least 3 months prior to screening.
  • Taking metformin only or metformin in addition to no more than two of the following: DPP-4 (DiPeptidyl Peptidase-4), SGLT-2 (Sodium-GLucose coTransporter-2), or TZD (Thiazolidinediones).
  • (BMI) of up to 40 kg/m2 at Screening and stable weight, with no more than 5 kg gain or loss in the 3 months prior to Screening.
  • Renal function - (estimated glomerular filtration rate) > 30 ml/min/1.73 m2
  • Females of must have a negative serum pregnancy test result at Screening.

Exclusion criteria

Exclusion Criteria:

  • Subjects with insulin-dependent diabetes

    1. has a history of type 1 diabetes mellitus or a history of ketoacidosis, or subject is assessed by the investigator as possibly having type 1 diabetes mellitus confirmed by a C-peptide \<0.7 ng/mL (0.23 nmol/L).
    2. has a history of other specific types of diabetes (e.g., genetic syndromes, secondary pancreatic diabetes, diabetes due to endocrinopathies, drug- or chemical-induced, and post-organ transplant).
  • Treatment with glucosidase inhibitor, insulin secretagogues (other than sulfonylureas), glucagon-like peptide 1 (GLP-1) agonists within 3 months prior to Visit 1.
  • History of any basal, pre-mix or prandial insulin (greater than 7 days) within 6 months prior to Screening.
  • History of >2 episodes of severe hypoglycemia within 6 months prior to Screening.
  • History of hypoglycemic unawareness (episodes of severe hypoglycemia with seizure or requiring third-party intervention or documented low blood glucose without associated autonomic symptoms)
  • Subjects with the following secondary complications of diabetes:

    1. Active proliferative retinopathy as confirmed by a dilated ophthalmoscopy/retinal photography examination performed (by a qualified person as per the country legislation) within 6 months prior to Screening.
    2. Renal dysfunction: \< 30 ml/min/1.73 m2
    3. History of proliferative retinopathy or severe form of neuropathy or cardiac autonomic neuropathy (CAN)
    4. Uncontrolled or untreated severe hypertension defined as systolic blood pressure above or equal to 180 mmHg and/or diastolic blood pressure above or equal to 120 mmHg
    5. Presence of unstable angina or myocardial infarction within 6 months prior to Screening, Grade 3 or 4 congestive heart failure (CHF) according to the (NYHA) criteria, valvular heart disease, cardiac arrhythmia requiring treatment, pulmonary hypertension, cardiac surgery, history/occurrence of coronary angioplasty and/or stroke or (TIA) within 6 months prior to Screening.
  • Subjects with psychiatric disorders which, per investigator judgment may have an impact on the safety of the subject or interfere with the subject's participation or compliance in the study.
  • Subjects who needed (in the last 12 months) or may require systemic (oral, intravenous, intramuscular) therapy for more than 2 weeks during the study period.
    1. Laboratory abnormalities at Screening include:

      1. C-peptide \< 1.0 ng/mL
      2. Abnormal serum thyrotropin (TSH) levels below the lower limit of normal or >1.5X the
      3. Elevated liver enzymes ( (ALT), alanine aminotransferase (AST), alkaline phosphatase) >2X the upper limit of normal.
      4. Very high triglyceride levels (>600 mg/dL); a single repeat test is allowable.
      5. Any relevant abnormality that would interfere with the efficacy or the safety assessments during the study treatment administration.
  • Positive history of active liver disease (other than non-alcoholic hepatic steatosis), including chronic or C, primary biliary cirrhosis, or active symptomatic gallbladder disease.
  • Positive history of .
  • Use of the following medications:

    1. History of any basal, pre-mix or prandial insulin (greater than 7 days) within 6 months prior to Screening.
    2. Administration of thyroid preparations or thyroxine (except in subjects on stable replacement therapy) within 6 weeks prior to Screening.
    3. Administration of systemic long-acting corticosteroids within two months or prolonged use (more than one week) of other systemic corticosteroids or inhaled corticosteroids (if daily dosage is > 1,000 μg equivalent beclomethasone) within 30 days prior to Screening. Intra-articular and/or topical corticosteroids are not considered systemic.
    4. Use of medications known to modify glucose metabolism or to decrease the ability to recover from hypoglycemia such as oral, parenteral, and inhaled steroids (as discussed above), and or immunomodulating agents.
  • Known allergy to soy.
  • Subject is on a weight loss program and is not in the maintenance phase or subject has started weight loss medication (e.g., orlistat or liraglutide), within 8 weeks prior to Screening.
  • Subject has had bariatric surgery.
  • Subject is pregnant or breastfeeding.
  • Subject is a user of recreational or illicit drugs or has had a recent history (within 1 year of Screening) of drug or alcohol abuse or dependence. (Note: Alcohol abuse includes heavy alcohol intake as defined by >3 drinks per day or >14 drinks per week, or binge drinking) at Screening. Occasional intermittent use of cannabinoid products will be allowed provided that no cannabinoid products have been used during the 1 week prior to each visit.
  • One or more to metformin as per local label.
  • History of gastrointestinal disorders (e.g. hypochlorhydria) with the potential to interfere with drug absorption.
  • At the Principal Investigator's discretion, any condition or other factors that are deemed unsuitable for subject enrollment into the study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
373 participants (actual)

Study arms

  • Active comparator
    Cohort A: ORMD-0801 once daily - QHS

    Dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes)

    Drug: Cohort A: ORMD-0801

  • Active comparator
    Cohort A: ORMD-0801 twice daily - BID

    Dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast.

    Drug: Cohort A: ORMD-0801

  • Active comparator
    Cohort A: ORMD-0801 three times daily - TID

    ORMD-0801 three times daily - TID: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast and lunch.

    Drug: Cohort A: ORMD-0801

  • Placebo comparator
    Cohort A: Matched Placebo Oral Capsule

    Placebo matched to one of the three active comparator arms. (either QHS, BID, or TID)

    Drug: Placebo oral capsule

  • Placebo comparator
    Cohort A: Excipient-Matched Placebo three times daily-TID

    Excipient matched placebo in a non-randomized single-blind fashion, TID, dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast and lunch. This is an exploratory arm, per FDA. The results of this arm are not included in the primary analysis.

    Drug: Placebo oral capsule

  • Active comparator
    Cohort B:ORMD-0801, 8 mg once daily - QHS:

    ORMD-0801 8 mg once daily - QHS: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes)

    Drug: Cohort B: ORMD-0801

  • Active comparator
    Cohort B: ORMD-0801 8 mg twice daily - BID

    ORMD-0801 8 mg twice daily - BID: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast.

    Drug: Cohort B: ORMD-0801

  • Active comparator
    Cohort B: ORMD-0801 16 mg once daily - QHS:

    ORMD-0801 16 mg once daily - QHS: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes)

    Drug: Cohort B: ORMD-0801

  • Active comparator
    Cohort B: ORMD-0801 16 mg twice daily - BID

    ORMD-0801 16 mg twice daily - BID: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast.

    Drug: Cohort B: ORMD-0801

  • Placebo comparator
    Cohort B - Matched Placebo Oral Capsule

    Cohort B - Matched Placebo Oral Capsule: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes)

    Drug: Placebo oral capsule

Interventions

  • Part 1 In the first two weeks of active treatment (Part 1) subjects will receive double-blind therapy according to their randomized regimen (placebo or ORMD-0801) to be taken QHS, BID or TID. Subjects will undergo a step-wise dose escalation from a starting dose of 16 mg (Visit 3), to 24 mg (Visit 4), to a top dose of 32 mg (Visit 5 onward). Subjects will then enter Part 2. Part 2: During Part 2, subjects will remain on fixed doses of ORMD-0801 (or matched placebo) for 10 weeks. Doses will not be adjusted unless clinically indicated for adverse events or hypoglycemia.

    Also known as: Oral Insulin

  • DrugPlacebo oral capsule

    Placebo provided QHS, BID, TID

    Also known as: SBTI, disodium EDTA, fish oil, aerosil, and TWEEN 80.

  • Part 1 In the first two weeks of active treatment, subjects will receive double-blind therapy according to their randomized regimen (ORMD 0801 8 mg or 16 mg, or matched placebo) to be taken QHS or BID. Subjects will then enter Part 2 at the same dose and regimen administered in Part 1. Part 2 Subjects will remain on fixed doses of ORMD-0801 (or matched placebo) for 10 weeks. Doses will not be adjusted unless clinically indicated for adverse events or hypoglycemia.

    Also known as: Oral Insulin

06

What researchers measure

Primary outcomes

  1. Change From Baseline of HbA1C (Glycated Hemoglobin)

    Least Squares Means change in HbA1C from baseline to Week 12 of the treatment period, where HbA1C is reported in units of percent. The change in HbA1c from baseline to Week 12 is expressed as a change in the value of HbA1C.

    Time frame: baseline (Run-in period, Week 0, Visit 1) and Week 12 (follow-up)

Secondary outcomes

  1. Mean Change From Baseline Over Time for HbA1C

    Mean change from baseline (Run-In, Week 0 Visit 1) to Part 1, Visit 3 for HbA1C (measured in mmols/mol)

    Time frame: Baseline (Run-In:Week 0, Visit 1) to Part 1, Visit 3, elapsed time: 3 weeks.

  2. Change Over Time in Hb1Ac

    Change of Hb1Ac from Baseline to Week 10, measured in mmol/mol

    Time frame: Baseline (week 0, visit 1) to Week 10, part 2

07

Results

Posted Nov 8, 2022

Participant flow

Patients were recruited into two primary Cohorts, A and B. Cohort A: 1. ORMD-0801 1X daily 2. ORMD-0801 2X daily 3. ORMD-0801 3X daily 4. Matched Placebo Sub-Cohort A 20 subjects Per FDA, excipient matched placebo; randomized single-blind, TID, same schedule as for Cohort A. Not part of primary analysis. Cohort B: 1. ORMD-0801 8 mg 1X daily 2. ORMD-0801 8 mg 2X daily 3. ORMD-0801 16 mg 1X daily 4. ORMD-0801 16 mg 2X daily 5. Excipient matched placebo once daily

Participant flow — Overall Study
MilestoneCohort A: ORMD-0801 Once Daily - QHSCohort A: ORMD-0801 Twice Daily - BIDCohort A: ORMD-0801 Three Times Daily - TIDCohort A: Matched Placebo Oral CapsuleCohort A (Sub-Cohort A): Excipient-Matched Placebo Three Times Daily-TIDCohort B:ORMD-0801, 8 mg Once Daily - QHS:Cohort B: ORMD-0801 8 mg Twice Daily - BIDCohort B: ORMD-0801 16 mg Once Daily - QHS:Cohort B: ORMD-0801 16 mg Twice Daily - BIDCohort B - Matched Placebo Oral Capsule
Started69686966201517181516
Completed62585856191315161114
Not completed7101110122242

Outcome measures

PrimaryChange From Baseline of HbA1C (Glycated Hemoglobin)

Least Squares Means change in HbA1C from baseline to Week 12 of the treatment period, where HbA1C is reported in units of percent. The change in HbA1c from baseline to Week 12 is expressed as a change in the value of HbA1C.

Time frame:
baseline (Run-in period, Week 0, Visit 1) and Week 12 (follow-up)
Reported as:
Least squares mean · percent HbA1C
Change From Baseline of HbA1C (Glycated Hemoglobin)
percent HbA1CCombined Cohort A +Cohort B: Matched-Placebo Oral CapsuleCohort A: ORMD-0801 Once Daily - QHSCohort A: ORMD-0801 Twice Daily - BIDCohort A: ORMD-0801 Three Times Daily - TIDCohort B:ORMD-0801, 8 mg Once Daily - QHS:Cohort B: ORMD-0801 8 mg Twice Daily - BIDCohort B: ORMD-0801 16 mg Once Daily - QHS:Cohort B: ORMD-0801 16 mg Twice Daily - BID
Change From Baseline of HbA1C (Glycated Hemoglobin)-0.13 (-0.86 to 0.59)-0.60 (-1.37 to 0.16)-0.59 (-1.32 to 0.14)-0.51 (-1.27 to 0.25)-0.95 (-1.87 to -0.03)-0.95 (-1.84 to -0.07)0.12 (-0.80 to 1.04)-0.50 (-1.47 to 0.48)
SecondaryMean Change From Baseline Over Time for HbA1C

Mean change from baseline (Run-In, Week 0 Visit 1) to Part 1, Visit 3 for HbA1C (measured in mmols/mol)

Time frame:
Baseline (Run-In:Week 0, Visit 1) to Part 1, Visit 3, elapsed time: 3 weeks.
Reported as:
Least squares mean · mmol/mol
Mean Change From Baseline Over Time for HbA1C
mmol/molCombined Cohort A+Cohort B: Matched-Placebo Oral CapsuleCohort A: ORMD-0801 Once Daily - QHSCohort A: ORMD-0801 Twice Daily - BIDCohort A: ORMD-0801 Three Times Daily - TIDCohort B:ORMD-0801, 8 mg Once Daily - QHS:Cohort B: ORMD-0801 8 mg Twice Daily - BIDCohort B: ORMD-0801 16 mg Once Daily - QHS:Cohort B: ORMD-0801 16 mg Twice Daily - BID
Mean Change From Baseline Over Time for HbA1C-2.12 (-4.40 to 0.16)-2.56 (-4.94 to -0.19)-1.95 (-4.21 to 0.30)-2.91 (-5.25 to -0.57)-3.26 (-6.13 to -0.39)-5.51 (-8.30 to -2.73)-2.06 (-4.94 to 0.82)-1.87 (-4.72 to 0.98)
SecondaryChange Over Time in Hb1Ac

Change of Hb1Ac from Baseline to Week 10, measured in mmol/mol

Time frame:
Baseline (week 0, visit 1) to Week 10, part 2
Reported as:
Least squares mean · mmol/mol
Change Over Time in Hb1Ac
mmol/molCohort A+Cohort B: Combined Matched Placebo Oral CapsuleCohort A: ORMD-0801 Once Daily - QDCohort A: ORMD-0801 Twice Daily - BIDCohort A: ORMD-0801 Three Times Daily - TIDCohort B:ORMD-0801, 8 mg Once Daily - QDCohort B: ORMD-0801 8 mg Twice Daily - BIDCohort B: ORMD-0801 16 mg Once Daily - QDCohort B: ORMD-0801 16 mg Twice Daily - BID
Change Over Time in Hb1Ac-1.27 (-8.88 to 6.35)-5.95 (-14.05 to 2.16)-4.95 (-12.62 to 2.73)-6.16 (-14.22 to 1.90)-10.34 (-20.01 to -0.68)-10.71 (-20.02 to -1.40)-0.25 (-9.94 to 9.44)-4.66 (-14.61 to 5.28)

Adverse events

Collected over Each subject was followed for a period of 12 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Combined Cohort A + Cohort B: Matched Placebo0/82 (0%)0/82 (0%)11/82 (13.4%)
Cohort A: ORMD-0801 Once Daily - QD0/69 (0%)5/69 (7.2%)19/69 (27.5%)
Cohort A: ORMD-0801 Twice Daily - BID0/68 (0%)0/68 (0%)6/68 (8.8%)
Cohort A: ORMD-0801 Three Times Daily - TID0/69 (0%)3/69 (4.3%)10/69 (14.5%)
Cohort B:ORMD-0801, 8 mg Once Daily - QD0/15 (0%)0/15 (0%)5/15 (33.3%)
Cohort B: ORMD-0801 8 mg Twice Daily - BID0/17 (0%)0/17 (0%)2/17 (11.8%)
Cohort B: ORMD-0801 16 mg Once Daily - QD0/18 (0%)0/18 (0%)1/18 (5.6%)
Cohort B: ORMD-0801 16 mg Twice Daily - BID0/15 (0%)1/15 (6.7%)2/15 (13.3%)
Excipient Matched Placebo -TID1/20 (5%)3/20 (15%)13/20 (65%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventCombined Cohort A + Cohort B: Matched PlaceboCohort A: ORMD-0801 Once Daily - QDCohort A: ORMD-0801 Twice Daily - BIDCohort A: ORMD-0801 Three Times Daily - TIDCohort B:ORMD-0801, 8 mg Once Daily - QDCohort B: ORMD-0801 8 mg Twice Daily - BIDCohort B: ORMD-0801 16 mg Once Daily - QDCohort B: ORMD-0801 16 mg Twice Daily - BIDExcipient Matched Placebo -TID
Chest PainGeneral disorders0/820/690/681/690/150/170/181/150/20
Acute Myocardial InfarctionCardiac disorders0/820/690/681/690/150/170/180/151/20
Myocardial InfarctionCardiac disorders0/820/690/680/690/150/170/180/151/20
DeathGeneral disorders0/820/690/680/690/150/170/180/151/20
OsteomyelitisInfections and infestations0/820/690/680/690/150/170/180/151/20
PneumoniaInfections and infestations—0/690/680/690/150/170/180/151/20
Atrial FibrillationCardiac disorders0/822/690/680/690/150/170/180/150/20
Angina PectorisCardiac disorders0/821/690/680/690/150/170/180/150/20
Coronary Artery DiseaseCardiac disorders0/820/690/681/690/150/170/180/150/20
Supraventricular TachycardiaCardiac disorders0/821/690/680/690/150/170/180/150/20
Most frequent other events
Showing 10 of 40
Most frequent other events
EventCombined Cohort A + Cohort B: Matched PlaceboCohort A: ORMD-0801 Once Daily - QDCohort A: ORMD-0801 Twice Daily - BIDCohort A: ORMD-0801 Three Times Daily - TIDCohort B:ORMD-0801, 8 mg Once Daily - QDCohort B: ORMD-0801 8 mg Twice Daily - BIDCohort B: ORMD-0801 16 mg Once Daily - QDCohort B: ORMD-0801 16 mg Twice Daily - BIDExcipient Matched Placebo -TID
DiarrhoeaGastrointestinal disorders3/822/693/688/691/150/170/180/153/20
Atrial FibrillationCardiac disorders0/823/691/680/690/150/170/180/152/20
ConstipationGastrointestinal disorders0/821/690/680/691/150/170/180/150/20
NauseaGastrointestinal disorders1/822/690/681/691/150/170/181/150/20
HypersensitivityImmune system disorders0/820/690/680/691/150/170/180/150/20
CystitisGastrointestinal disorders1/820/690/680/691/151/170/180/150/20
DiverticulitisInfections and infestations0/820/690/680/690/150/170/181/150/20
AnemiaBlood and lymphatic system disorders0/823/691/680/690/151/171/180/150/20
Atrioventricular Block First DegreeCardiac disorders0/821/690/680/690/150/170/180/151/20
PalpitationsCardiac disorders1/820/690/680/690/150/170/180/151/20

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cohort A+Cohort B Combined: Matched Oral Capsule PlaceboCohort A: ORMD-0801 Once Daily - QDCohort A: ORMD-0801 Twice Daily - BIDCohort A: ORMD-0801 Three Times Daily - TIDCohort B:ORMD-0801, 8 mg Once Daily - QDCohort B: ORMD-0801 8 mg Twice Daily - BIDCohort B: ORMD-0801 16 mg Once Daily - QDCohort B: ORMD-0801 16 mg Twice Daily - BIDSub-Cohort A: Excipient Matched PlaceboTotal
Mean55.92 ± 9.91456.72 ± 10.76655.68 ± 10.56955.22 ± 11.66353.66 ± 8.2256.87 ± 9.13254.98 ± 11.22954.98 ± 11.78564.08 ± 9.21855.73 ± 10.544
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A+Cohort B Combined: Matched Oral Capsule PlaceboCohort A: ORMD-0801 Once Daily - QDCohort A: ORMD-0801 Twice Daily - BIDCohort A: ORMD-0801 Three Times Daily - TIDCohort B:ORMD-0801, 8 mg Once Daily - QDCohort B: ORMD-0801 8 mg Twice Daily - BIDCohort B: ORMD-0801 16 mg Once Daily - QDCohort B: ORMD-0801 16 mg Twice Daily - BIDSub-Cohort A: Excipient Matched PlaceboTotal
Female3327232957748143
Male494245401010111112230
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort A+Cohort B Combined: Matched Oral Capsule PlaceboCohort A: ORMD-0801 Once Daily - QDCohort A: ORMD-0801 Twice Daily - BIDCohort A: ORMD-0801 Three Times Daily - TIDCohort B:ORMD-0801, 8 mg Once Daily - QDCohort B: ORMD-0801 8 mg Twice Daily - BIDCohort B: ORMD-0801 16 mg Once Daily - QDCohort B: ORMD-0801 16 mg Twice Daily - BIDSub-Cohort A: Excipient Matched PlaceboTotal
Hispanic or Latino4836373698980191
Not Hispanic or Latino33322933669620174
Unknown or Not Reported1120030108
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort A+Cohort B Combined: Matched Oral Capsule PlaceboCohort A: ORMD-0801 Once Daily - QDCohort A: ORMD-0801 Twice Daily - BIDCohort A: ORMD-0801 Three Times Daily - TIDCohort B:ORMD-0801, 8 mg Once Daily - QDCohort B: ORMD-0801 8 mg Twice Daily - BIDCohort B: ORMD-0801 16 mg Once Daily - QDCohort B: ORMD-0801 16 mg Twice Daily - BIDSub-Cohort A: Excipient Matched PlaceboTotal
American Indian or Alaska Native0001000001
Asian0021001206
Native Hawaiian or Other Pacific Islander1111000004
Black or African American117883411346
White695957581211161117310
More than one race0000000000
Unknown or Not Reported1200020106
BMI
BMI(Kg/M^2)Cohort A+Cohort B Combined: Matched Oral Capsule PlaceboCohort A: ORMD-0801 Once Daily - QDCohort A: ORMD-0801 Twice Daily - BIDCohort A: ORMD-0801 Three Times Daily - TIDCohort B:ORMD-0801, 8 mg Once Daily - QDCohort B: ORMD-0801 8 mg Twice Daily - BIDCohort B: ORMD-0801 16 mg Once Daily - QDCohort B: ORMD-0801 16 mg Twice Daily - BIDSub-Cohort A: Excipient Matched PlaceboTotal
Mean31.137 ± 4.775031.721 ± 4.940930.447 ± 4.771031.191 ± 4.004531.759 ± 4.439331.005 ± 5.033331.881 ± 6.051430.776 ± 5.453031.310 ± 5.597631.171 ± 4.7203
HbA1c
HbA1c(percent HbA1c)Cohort A+Cohort B Combined: Matched Oral Capsule PlaceboCohort A: ORMD-0801 Once Daily - QDCohort A: ORMD-0801 Twice Daily - BIDCohort A: ORMD-0801 Three Times Daily - TIDCohort B:ORMD-0801, 8 mg Once Daily - QDCohort B: ORMD-0801 8 mg Twice Daily - BIDCohort B: ORMD-0801 16 mg Once Daily - QDCohort B: ORMD-0801 16 mg Twice Daily - BIDSub-Cohort A: Excipient Matched PlaceboTotal
Mean9.46 ± 1.4348.96 ± 1.2819.36 ± 1.6569.64 ± 1.5789.83 ± 1.7598.46 ± 1.1048.96 ± 1.4209.18 ± 1.6878.93 ± 0.9299.31 ± 1.512
Diabetes Medications
Diabetes Medications(Participants)Cohort A+Cohort B Combined: Matched Oral Capsule PlaceboCohort A: ORMD-0801 Once Daily - QDCohort A: ORMD-0801 Twice Daily - BIDCohort A: ORMD-0801 Three Times Daily - TIDCohort B:ORMD-0801, 8 mg Once Daily - QDCohort B: ORMD-0801 8 mg Twice Daily - BIDCohort B: ORMD-0801 16 mg Once Daily - QDCohort B: ORMD-0801 16 mg Twice Daily - BIDSub-Cohort A: Excipient Matched PlaceboTotal
Metformin Alone2220201265756103
Metformin, No Sulfonylureas, but At Least 1 Other Medication13108121012148
Metformin with Sulfonylureas Only3330263377834151
Metformin with Sulfonylureas and Other Medication(s)105860113640
Not on Metformin, But On 1 Other Medication44341201120
Not on Metformin, But On At Least 2 Other Medications00320211211
08

Study locations

1 site
  • AA MRC
    Flint, Michigan 48504, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in Oct 2019, 16 months.

Results were first posted in Nov 2022, 3 years after primary completion.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 16 months is above that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2018
First posted
Mar 16, 2018
StartActual
May 29, 2018
Primary completionActual
Oct 21, 2019
CompletionActual
Feb 18, 2020
Results first posted
Nov 8, 2022
Last update
Nov 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03467932
Lead sponsor
Oramed, Ltd.
Collaborators
Integrium
Responsible party
Sponsor
First posted
Mar 16, 2018
Start date
May 29, 2018
Primary completion
Oct 21, 2019
Completion
Feb 18, 2020
Results posted
Nov 8, 2022
Last update
Nov 8, 2022

Study contacts

Joel M Neutel, M. D.
principal investigator · Orange County Research Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ORMD-0801

Start the discussion